Coloplast A/S (OTCMKTS:CLPBY) Upgraded by Royal Bank of Canada to Moderate Buy Rating

Coloplast A/S (OTCMKTS:CLPBY) was upgraded by research analysts at Royal Bank of Canada from a “hold” rating to a “moderate buy” rating in a note issued to investors on Monday,Zacks.com reports.

Other equities analysts have also issued reports about the stock. Hsbc Global Res raised shares of Coloplast A/S from a “moderate sell” rating to a “hold” rating in a research report on Monday, November 18th. UBS Group raised shares of Coloplast A/S from a “strong sell” rating to a “hold” rating in a research note on Wednesday, December 11th. Finally, Sanford C. Bernstein raised shares of Coloplast A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 28th.

Coloplast A/S Stock Up 1.1 %

OTCMKTS CLPBY opened at $11.10 on Monday. The company has a current ratio of 1.02, a quick ratio of 0.66 and a debt-to-equity ratio of 0.92. The stock has a 50 day moving average price of $11.11 and a 200-day moving average price of $12.26. Coloplast A/S has a one year low of $10.54 and a one year high of $14.34.

Coloplast A/S (OTCMKTS:CLPBY) last issued its earnings results on Tuesday, February 4th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.01). Coloplast A/S had a return on equity of 28.60% and a net margin of 17.81%. On average, equities analysts forecast that Coloplast A/S will post 0.31 EPS for the current year.

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.